Message Font: Serif | Sans-Serif
 
No. of Recommendations: 2
andrea,
we desperatly need new antibiotics - big pharma has abandoned its development 25 years ago (reasons: no maintainance rx, risk of bacterial resistance, short lifecycle etc.). I know it first hand as I was marketing manager @ Merck Switzerland for imipenem (Tienam)...
In the past years I made some good money when Trius was swallowed by Cubist followed by the takeover of Cubist by Merck!
The rejection of Cempra's soli on Dec 28, 2016, was a real shock to me and it is still unbelievable. I am still holding a position but increased my positions in Paratek [PRTK] and AKAO. To me Tetraphase [TTPH] is the least attractive antibiotic company at the moment. I will explain this in detail in another post later on. Okay!?
The second field of specific interest is ImmunoOncology. I am looking forward to ASCO 2017: NLNK, CALA, CLDX, REGN, INO and DVAX will present their data. I will give some feedback on this board.
Take care, marsuculix
Print the post  

Announcements

What was Your Dumbest Investment?
Share it with us -- and learn from others' stories of flubs.
When Life Gives You Lemons
We all have had hardships and made poor decisions. The important thing is how we respond and grow. Read the story of a Fool who started from nothing, and looks to gain everything.
Contact Us
Contact Customer Service and other Fool departments here.
Work for Fools?
Winner of the Washingtonian great places to work, and Glassdoor #1 Company to Work For 2015! Have access to all of TMF's online and email products for FREE, and be paid for your contributions to TMF! Click the link and start your Fool career.